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Abstract
Anti-ischemic therapy, in particular beta-blockers, is the most commonly employed drug for the
control of myocardial ischemia in patients with stable coronary artery disease. Its widespread use
also in patients with suspected coronary artery disease has important practical, clinical diagnostic
and prognostic implications because diagnostic tests are heavily influenced by its effects. In the
present review, the pathophysiological mechanisms of ischemia protection by antianginal therapy
are described. Not all stressors are created equal in front of the different classes of antianginal
drugs and on their turn the different classes of drugs exert different levels of protection on
inducible ischemia. Several clinical implications can be drawn: From the diagnostic viewpoint
antianginal therapy decreases test sensitivity, offsetting the real ischemic burden for a too high
percentage of false negative tests. From the prognostic viewpoint test positivity in medical therapy
identifies a group of subjects at higher risk of experiencing cardiac death and positivity on medical
therapy can be considered a parameter of ischemia severity. Nonetheless in patients with known
coronary artery disease the ability of antianginal therapy to modify the ischemic threshold at stress
testing represent a powerful means to assess therapy efficacy. From a practical viewpoint, the use
of antianginal therapy at time of testing has advantages and disadvantages which are largely
dependent on the purpose a test is performed: if the purpose of testing is to diagnose ischemia, it
should be performed in the absence of antianginal medications. If the purpose of testing is to assess
the protective effects of antianginal therapy, the test should be performed on medications.
Background
Anti-ischemic therapy, in particular beta-blockers, is the
most commonly employed drug for the control of myo-
cardial ischemia in patients with stable coronary artery
disease. Its widespread use also in patients with suspected
coronary artery disease has important practical, clinical
diagnostic and prognostic implications because diagnos-
tic tests are heavily influenced by its effects. The diagnostic
and prognostic impact of anti-ischemic therapy on stress
testing is largely ignored but not negligible. The issue
raises several questions: How to evaluate patients at time
of testing for myocardial ischemia? How to interpret a
stress test performed on anti-ischemic therapy? Are the
stressors employed for the detection of myocardial
ischemia created equal in relation to the different classes
of drugs used in clinical practice? Is stress testing able to
assess the efficacy of medical therapy in patients with
known coronary artery disease? Has the protection of anti-
ischemic therapy on inducible myocardial ischemia any
impact on long-term survival?
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Pathophysiologic implications of anti-ischemic 
therapy during stress testing
The answer to all these issues relies on the mechanism
through which myocardial ischemia is induced by the dif-
ferent stressors (exercise or pharmacologic such as dipyri-
damole and dobutamine) employed during stress testing.
Test exploring organic coronary artery stenosis can induce
ischemia by two basic mechanisms: 1. an increase in oxy-
gen demand, exceeding the fixed supply and 2. flow mald-
istribution due to inappropriate coronary arteriolar
triggered by a metabolic/pharmacologic stimulus [1]. The
mechanism of increased demand can be easily fitted into
the familiar concept framework of ischemia as a supply-
demand mismatch, deriving from an increase in oxygen
requirements in the presence of a fixed reduction in coro-
nary flow reserve. The different stresses can determine
increases in demand through different mechanisms (Fig.
1). In resting conditions, myocardial oxygen consump-
tion is dependent mainly upon heart rate, inotropic state,
and the left ventricular wall stress (which is proportional
to the systolic blood pressure) [2]. Following dipyrida-
mole or adenosine administration, a slight increase in
myocardial function, a modest decrease in blood pressure,
and mild tachycardia can be observed, overall determin-
ing only a trivial increase in myocardial oxygen demand
[3]. During exercise, the increase in heart rate, blood pres-
sure, and inotropic state accounts for the overall increase
in myocardial oxygen consumption [4]. Pacing and dob-
utamine also increase – to a lesser degree – myocardial
oxygen demand [5]. During pacing, the increase is mainly
due to the increased heart rate. Dobutamine markedly
increases contractility and heart rate. Further augment in
myocardial oxygen consumption for heart rate increase
occurs with the co-administration of atropine with dob-
utamine [6]. and dipyridamole [7]. (Fig. 2).
In the presence of coronary atherosclerosis, appropriate
arteriolar dilation can paradoxically exert detrimental
effects on regional myocardial perfusion, causing overper-
fusion of myocardial layers or regions already well per-
fused in resting conditions at the expense of regions or
layers with a precarious flow balance in resting conditions
[8]. Anti-ischemic therapy can interfere with all the above
mentioned mechanisms of ischemia induction, although
in a very different fashion. The mechanism of action of
anti-ischemic drugs is easily fitted within the familiar
framework of supply-demand mismatch. In particular,
beta-blockers are credited with reducing exercise-induced
ischemia by decreasing myocardial oxygen demand and
possibly by increasing supply through a reduction in
extravascular forces [9]. Experimental studies
demonstrated that beta-blockers reduce dipyridamole-
induced ischemia by an alteration of regional myocardial
blood flow [10]. However, this straightforward explana-
tion seems inadequate in justifying the protective effects
of beta-blockers on dipyridamole-induced ischemia.
Experimental data show that beta-blockers do not affect
the dipyiridamole-induced increase in flow [12]. On the
other hand, the increase in myocardial oxygen consump-
tion does not play any significant role in the induction of
dipyridamole-induced ischemia, which is due to an abso-
lute reduction in subendocardial flow (tightly linked to
regional wall thickening) mostly for "vertical" and "hori-
zontal" steal phenomena.
However, experimental studies on the model of the exer-
cising dog have shown that beta-blockers protect myocar-
dium from stress-induced myocardial blood flow-
function relation: for a given transmural flow, there is a
rise of subendocardial and a fall of subepicardial flow,
with an improved regional performance [10]. This same
mechanism has also been documented with some cal-
cium antagonists, such as diltiazem and may explain, in
part, the beneficial effects of this class of drugs on dipyri-
damole-induced ischemia. Calcium antagonists can effec-
tively prevent ischemia provoked by dipyridamole also
through other mechanisms, which they share with
nitrates, and they tend to increase the coronary flow sup-
ply during stress. In this case, the prevention of steal phe-
nomena may be due to the increase in collateral flow
(which has been shown with nitrates and, to a much lesser
extent, with some calcium antagonists) [12]. and to the
dilation of epicardial coronary lumen size. The pro-
nounced increase in collateral flow can prevent horizontal
steal phenomena due to dipyridamole, wheras even a
small increase of the coronary diameter can dramatically
reduce the blood pressure drop across the stenosis, there-
fore preventing vertical steal phenomena. Beta-blockers
exert a direct and competitive action on beta-1 receptors,
as they are employed as specific antagonists of dob-
utamine-induced ischemia. Dobutamine, through its
beta-1 agonist action determines the increase in oxygen
consumption, but it induces flow maldistribution
through beta-2 arteriolar receptors.
Diagnostic implications of the use of anti-
ischemic therapy during stress testing
On the basis of these premises and taking into considera-
tion that the markers of inducible myocardial ischemia
(electrocardiogram, perfusion, wall motion) are very dif-
ferent therefore expressing a different sensitivity to the
action of anti-ischemic therapy at time of testing, it is clear
that medical therapy affects test results (see table 1. In fact,
the AHA/ACC Guidelines on Chronic stable angina state
that [13]. "whenever possible, it is recommended that
beta-blockers (and other anti-ischemic drugs) be withheld
for four to five half-lives (usually about 48 h) before exer-
cise imaging studies for the diagnosis and initial risk
stratification of patients with suspected CAD". Ideally,
these drugs should be withdrawn gradually to avoid aCardiovascular Ultrasound 2004, 2:14 http://www.cardiovascularultrasound.com/content/2/1/14
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withdrawal phenomenon that may precipitate events.
When beta-blockers cannot be stopped, stress testing may
detect myocardial ischemia less reliably, but it usually will
still be positive in patients at the highest risk. The same
recommendations apply to imaging stress testing. None-
theless, in patients who exercise to a submaximal level
because of the effect of drugs, perfusion or echocardio-
graphic imaging still affords higher sensitivity than the
exercise ECG alone [14]. On the basis of these recommen-
Major determinants of myocardial oxygen consumption in resting conditions (left) and during stress commonly employed with  echocardiography Figure 1
Major determinants of myocardial oxygen consumption in resting conditions (left) and during stress commonly employed with 
echocardiography.
Conceptual allocation of tests employed in combination with  echocardiography to detect coronary artery disease stenosis  inducing ischemia via steal effect (left) or increased myocar- dial oxygen demand (right), or both mechanisms Figure 2
Conceptual allocation of tests employed in combination with 
echocardiography to detect coronary artery disease stenosis 
inducing ischemia via steal effect (left) or increased myocar-
dial oxygen demand (right), or both mechanisms.
Correlation between the therapy-induced variations in dipy- ridamole and exercise time in the 38 patients with positivity  of both tests off treatment (Modified from 21) Figure 3
Correlation between the therapy-induced variations in dipy-
ridamole and exercise time in the 38 patients with positivity 
of both tests off treatment (Modified from 21).
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dations patients undergoing a stress testing for diagnostic
purposes should be evaluated off therapy not to offset test
results. Exercise imaging stress (nuclear perfusion or ultra-
sound) testing have a lower sensitivity when performed
on anti-ischemic therapy [14-19]. due to the limited
increase in heart rate and blood pressure which determine
oxygen consumption. Antianginal therapy lowers the sen-
sitivity of exercise echocardiography as it does with
vasodilator stress testing [19,20]. Antianginal therapy
with beta-blockers, calcium-antagonists or nitrates in var-
ious combinations prevent dipyridamole-induced
ischemia by delaying the appearance of the transient dys-
synergy [21]. this variation on dipyridamole time parallels
variations in exercise time at exercise stress testing [21].
(Fig. 3). Dipyridamole stress sensitivity was 91% off ther-
apy and fell to 65% under therapy in various combina-
tions (beta-blockers and/or calcium antagonists and/or
nitrates). The same reduction of dipyridamole test sensi-
tivity is obtained with monotherapy with beta-blockers at
Dipyridamole test sensitivity on and off beta-blocking therapy  (Modified from 23) Figure 4
Dipyridamole test sensitivity on and off beta-blocking therapy 
(Modified from 23). Test sensitivity is significantly reduced in 
patients studied on beta-blocking therapy.
Heart rate during dobutamine-atropine stress testing on and  off beta-blockers (Modified from 25) Figure 5
Heart rate during dobutamine-atropine stress testing on and 
off beta-blockers (Modified from 25).
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Dobutamine-atropine stress echocardiography test sensitiv- ity in patients on and off non-beta blocking therapy (Modified  from 26) Figure 6
Dobutamine-atropine stress echocardiography test sensitiv-
ity in patients on and off non-beta blocking therapy (Modified 
from 26).
Schematic illustration of the principle underlying the impact  of antianginal therapy on different markers of ischemia:  regional function and perfusion imaging Figure 7
Schematic illustration of the principle underlying the impact 
of antianginal therapy on different markers of ischemia: 
regional function and perfusion imaging. At rest, perfusion is 
homogeneously distributed between endocardial and epicar-
dial layers. In the presence of a significant coronary stenosis, 
vasodilation induced by pharmacologic stress, provokes a 
subendocardial underperfusion with a relative epicardial 
overperfusion which is translated into an impairment of func-
tion (echocardiographic dyssynergy) and perfusion (reversi-
ble defect at scintigraphy). Medical therapy at time of testing 
re-equilibrates the imbalance between subendocardial and 
subepicardial layers, but it affects only function.
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time of testing (100% off therapy vs. 38% on therapy)
[22,23]. (Fig. 4). Interestingly, the positive effects of beta-
blockers on dipyridamole stress are largely independent
of the effect on heart rate, possibly involving a direct anti-
steal effect [21-23]. Angiotensin-converting enzyme
inhibitors have no effect on dipyridamole stress echocar-
diography results [24]. The sensitivity of dobutamine is
heavily affected by concomitant beta-blocker therapy.
Beta-blockers effect a rightward shift in the dose-response
curve to dobutamine and sharply lower test sensitivity,
unless atropine is used [25]. (Fig. 5). Calcium antagonists
and/or nitrates only mildly reduce dobutamine stress sen-
sitivity (100% off therapy vs.88% on therapy, p=ns) (Fig.
6). Non-beta-blocker antianginal therapy reduces the
severity of dobutamine-induced ischemia by reducing the
value of peak wall motion score index and time of
ischemia appearance. However, these changes are not cor-
related to variations in exercise tolerance [26].
Dipyridamole stress nuclear imaging techniques do not
seem to be influenced by anti-ischemic therapy [27].
However, it has been recently demonstrated that acute
administration of beta-blockers in patients with known
coronary artery disease reduces dipyridamole SPECT sen-
sitivity from 69% with placebo to 52% (p = 0.039) with
10 or 20 mg of metoprolol in a per-vessel analysis, but not
overall sensitivity [28]. The reason for this difference
between stress echocardiography and nuclear imaging is
likely to be related to the different markers of ischemia,
i.e. wall motion abnormalities vs. perfusion, in the face of
the same pathophysiologic mechanism of ischemia: the
reduction of coronary reserve. In fact, in the presence of a
coronary stenosis, during stress, flow remains elevated in
the subepicardial layer but falls in the subepicardium.
This selective stress-induced hypoperfusion is important
for stress echocardiography, since the regional systolic
thickening is linearly and closely related to subendocar-
dial perfusion and only loosely related to subepicardial
perfusion [29,30]. (Fig. 7).
Prognostic implications of anti-ischemic therapy 
during stress testing
The protective effect of anti-ischemic therapy on inducible
myocardial ischemia might exert a powerful impact on
prognosis. From the EPIC-EDIC Data bank, it has been
analyzed the prognostic impact of antianginal therapy at
time of testing in 7333 patients with suspected or known
coronary artery disease undergoing pharmacologic stress
echocardiography with either dipyridamole or dob-
utamine. The results show that a positive test on medical
therapy is an additional marker of ischemia severity at
stress testing whereas a negative test on medical therapy is
less prognostically benign, being a false negative result
[31]. (Fig. 8). No prognostic difference was found among
the various forms of anti-ischemic drugs at time of testing,
but the presence per se of antinaginal therapy at time of
testing is an independent predictor of death. It is worth
noting that in the study only a very low percentage of
patients was taking beta-blockers: if on one side this
aspect represent a clear lack of adherence to recommenda-
tions [13]., on the other it is an observed pattern of pre-
scription in our data base, which simply reflected the
clinical practice and the lack of a universally accepted pol-
icy of testing regarding concomitant therapy [32,33].
Marwick et al. [34]. have demonstrated a protective effect
on mortality of beta-blocker therapy in patients with a
negative exercise echocardiography whereas specificity
and negative predictive value is increased for the predic-
tion of cardiac events (cardiac death, myocardial infarc-
tion and unstable angina) during exercise scintigraphy in
patients evaluated off medical therapy at time of testing
[35].
The clinical implications of these results are far-reaching.
Inducible myocardial ischemia during pharmacological
stress testing on medical therapy identifies the subset of
patients at highest risk of death. On these patients an
aggressive approach has to be undertaken in order to
change the natural history of coronary artery disease. On
the far opposite end the incidence of death in patients
with a negative pharmacologic test off therapy is so low
Kaplan-Meier survival curves (considering total mortality as  an endpoint) in patients stratified according to presence  (DET +) or absence (DET -) of myocardial ischemia at phar- macological stress echocardiography on and off antianginal  medical therapy Figure 8
Kaplan-Meier survival curves (considering total mortality as 
an endpoint) in patients stratified according to presence 
(DET +) or absence (DET -) of myocardial ischemia at phar-
macological stress echocardiography on and off antianginal 
medical therapy. The best survival is observed in patients 
with no inducible ischemia off therapy; the worst survival in 
patients with inducible ischemia on therapy (Positive DET vs. 
Negative DET off antianginal medical therapy, p < 0.000; Pos-
itive DET vs. Negative DET on antianginal medical therapy, p 
< 0.074) (Modified from 31).
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that no intervention could lower the spontaneous rate of
death any further. At intermediate risk are those patients
with a negative test on medical therapy or with a positive
test off medical therapy. Different clinical scenarios can be
foreseen on the basis of the present results: 1) A negative
test on medical therapy might represent a false negative
result, therefore it is advisable to repeat the test off therapy
in order to assess the real ischemic burden through the
conventional stress echocardiographic parameters
[36,37]. – i.e. number of ischemic segments, severity of
induced dysfunction, (both expressed by peak wall
motion score index), pharmacologic load and time of
onset of ischemia. This is in line with the recommenda-
tions of the American Heart Association in patients with
stable angina [13].; 2) In the case of a positive test off
medical therapy, the effect of therapy can be assessed with
the advantage of using an objective, primary ischemic end
point such as changes in wall motion during stress.
Conclusions
Patients may be undergoing various forms of antianginal
therapy at the time of testing, both an advantage and a dis-
advantage for stress echocardiography testing. The
disadvantage is that antianginal therapy reduces sensitiv-
ity, since stress-induced wall motion abnormalities are
caused by the development of obligatory myocardial
ischemia. The advantage is that the effect of therapy can be
assessed using an objective, primary ischemic end-point
such as changes in stress-induced wall motion abnormal-
ities. The presence of ischemia can be titrated on the basis
of the ischemic-free stress time and the extent and severity
of the induced dyssynergy. The various forms of stress are
differently affected by various forms of therapy. In
patients with known or suspected coronary artery disease,
ongoing anti-ischemic therapy at the time of testing heav-
ily modulates the prognostic value of pharmacological
stress echo. In presence of concomitant anti-ischemic
therapy, a positive test is more prognostically malignant
and a negative test less prognostically benign. However,
the decision to remove a patient from beta-blocker ther-
apy for stress testing should be made on an individual
basis and should be done carefully to avoid a potential
hemodynamic rebound effect, which can lead to acceler-
ated angina or hypertension [38]. No major side effects
were recognized when medical therapy was withdrawn in
large series of consecutive patients undergoing
pharmacologic stress echocardiography [39]. In practical
terms, when a test is performed for diagnostic purposes it
should be done off medical therapy in order to avoid the
influence of medical therapy (in case of hypertensive
patients it is possible to prescribe ACE-inhibitors or Angi-
otensin II receptor blockers that do not exert any protec-
tive effect on myocardial ischemia). In patients with
known coronary artery disease the decision to suspend
medical therapy should be taken on an individual basis in
view also of the fact that pharmacologic stress echocardi-
ography is a versatile tool that can assess medical therapy
efficacy in the long term prognosis [31].
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